Moderna and Samsung Biologics sign fill-finish manufacturing deal

Moderna and Samsung Biologics, a contract development and manufacturing organization (CDMO), have reached a manufacturing services and supply agreement in which Samsung Biologics will deliver commercial fill-finish manufacturing for mRNA-1273, Moderna’s Covid-19 vaccine.

Once the deal is in motion, Samsung Biologics’ facilities in Incheon, South Korea, will begin providing aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of the vaccine intended for the supply of markets outside of the US, beginning in Q3.

“This vaccine is paramount to people around the world in the fight against the Covid-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,” says John Rim, CEO of Samsung Biologics. “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”